Peptide Vaccinations Plus GM-CT-01 in Melanoma

NCT01723813 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped due to end of validity of peptide vaccine

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2
BIOLOGICAL: Galectin-3 inhibitor: GM-CT-01 systemic injections
BIOLOGICAL: Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain